- Home
- GSRF vs AARD Comparison
GSRF vs AARD Comparison
Compare GSRF & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$14.56
Company Overview
Basic Information| Metric | GSRF | AARD |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.5M | 297.2M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GSRF | AARD |
|---|---|---|
| Price | $9.98 | $14.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $31.11 |
| AVG Volume (30 Days) | 87.7K | ★ 226.6K |
| Earning Date | 01-01-0001 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $184.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $4.88 |
| 52 Week High | $10.20 | $19.58 |
Technical Indicators
Market Signals| Indicator | GSRF | AARD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 62.48 |
| Support Level | N/A | $12.78 |
| Resistance Level | N/A | $13.62 |
| Average True Range (ATR) | 0.00 | 0.95 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 0.00 | 71.02 |
Price Performance
Historical Comparison GSRF
AARD
About GSRF GSR IV Acquisition Corp. Class A ordinary share
GSR IV Acquisition Corp is a blank check company.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.